{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:49:10Z","timestamp":1789019350527,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejca.2020.05.021","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T18:53:30Z","timestamp":1596567210000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands \u2013 A nationwide population-based study"],"prefix":"10.1016","volume":"137","author":[{"given":"Michiel C.T.","family":"van Zeijl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florine L.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte I.E.","family":"van Poelgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W.J.M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J.B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franchette W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozemarijn S.","family":"van Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"ten Tije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen H.W.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.05.021_bib1","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.28625","article-title":"Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis","volume":"134","author":"Bishop","year":"2014","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib2","first-page":"e23","article-title":"Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease","volume":"31","author":"Lerner","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ejca.2020.05.021_bib3","first-page":"1396","article-title":"Trends in incidence and survival in patients with melanoma, 1974-2013","volume":"9","author":"Che","year":"2019","journal-title":"Am J Canc Res"},{"key":"10.1016\/j.ejca.2020.05.021_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/apm.12529","article-title":"Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey","volume":"124","author":"Mikkelsen","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.ejca.2020.05.021_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2016.08.007","article-title":"Mucosal melanomas in the racially diverse population of California","volume":"76","author":"Altieri","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.05.021_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-018-0675-0","article-title":"Mucosal melanoma: a literature review","volume":"20","author":"Yde","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2020.05.021_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.05.021_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","article-title":"Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis","volume":"21","author":"Kuk","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","article-title":"KIT as an oncogenic driver in melanoma: an update on clinical development","volume":"20","author":"Meng","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2020.05.021_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in The Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib11","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2020.05.021_bib13","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2020.05.021_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.9074","article-title":"Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma","volume":"32","author":"Postow","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib15","first-page":"116","article-title":"An updated review of mucosal melanoma: survival meta-analysis","volume":"11","author":"Minhahn","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib16","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2020.05.021_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CMR.0000000000000306","article-title":"Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma","volume":"27","author":"Shoushtari","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.05.021_bib18","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-18-3442","article-title":"Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations","volume":"25","author":"Zhou","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.05.021_bib19","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s00330-015-3992-9","article-title":"Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study","volume":"26","author":"Gr\u00f6zinger","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2020.05.021_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1102\/1470-7330.2013.0055","article-title":"Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence","volume":"13","author":"O'Regan","year":"2013","journal-title":"Canc Imag"},{"key":"10.1016\/j.ejca.2020.05.021_bib21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw694","article-title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","volume":"28","author":"Lian","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib22","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib23","first-page":"162","article-title":"Recent treatment results for metastatic melanoma: data from the Dutch melanoma treatment registry","author":"Van Zeijl","year":"2018","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.ejca.2020.05.021_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib27","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","article-title":"Efficacy and safety of ipilimumab 3 mg\/kg in patients with pretreated, metastatic, mucosal melanoma","volume":"50","author":"Del Vecchio","year":"2014","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option 11 medical and Health sciences 1107 immunology 11 medical and Health sciences 1112 Oncology and carcinogenesis","volume":"6","author":"Rohaan","year":"2018","journal-title":"J Immunother Canc"},{"key":"10.1016\/j.ejca.2020.05.021_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14300","article-title":"Analysis of Chinese acral and mucosal melanoma patient genomic and neoantigen profiles in cancer vaccine development: a pilot study","volume":"37","author":"Guo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.05.021_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib34","article-title":"The mutational landscape of mucosal melanoma","author":"Nassar","year":"2019","journal-title":"Semin Canc Biol"},{"key":"10.1016\/j.ejca.2020.05.021_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.05.021_bib36","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.2217\/fon-2019-0465","article-title":"Survival outcomes of mucosal melanoma in the USA","volume":"15","author":"Al-Haseni","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib37","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1245\/s10434-018-6503-9","article-title":"Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients","volume":"25","author":"Cui","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.05.021_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.05.014","article-title":"Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma","volume":"81","author":"Heppt","year":"2017","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:28Z","timestamp":1760732908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"alternative-id":["S0959804920302987"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands \u2013 A nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}